Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

Fig. 1

a, b Kaplan–Meier curves for time to first MACE+ and MACE, respectively, in the meta-analysis. c, d Hazard ratios (HR) and 95 % CI for risk of MACE+, MACE, components, and all-cause death for treatment with BIL versus comparator insulin in the meta-analysis (c all patients; d type 2 diabetes). Comp comparator insulin; BIL basal insulin peglispro

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840